Trial Profile

A potentially registrational trial of IMVT-1402 of Myasthenia Gravis (MG)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Nov 2024 According to a Roivant Sciences media release, Immunovant now has active IND in Graves' Disease and expects to initiate potentially registrational trial in this indication by December 31, 2024.
06 Aug 2024 According to an Immunovant media release, company expects to initiate a potentially registrational program for IMVT-1402 in MG by March 31, 2025.
29 May 2024 According to an Immunovant media release, the company plans to initiate a potentially registrational program for IMVT-1402 in MG in this fiscal year based on results of batoclimab MG trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com